The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles
A leading gynaecologist at Aston Medical School is probing whether GLP-1 drugs like Ozempic and Mounjaro could transform care for women with PCOS. With a £60,000 NHS grant, Dr Shagaf Bakour aims to evaluate their effects on metabolic health and fertility. This investigation highlights hope for better treatment pathways amid rising interest in these weight loss jabs.
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
Amazon One Medical has launched a new weight management program featuring GLP-1 medications, providing transparent pricing and dedicated primary care oversight. With GLP-1 pills starting at $25 per month with insurance or $149 cash-pay, and injectables at $299, this initiative addresses key barriers like cost. Available nationwide with rapid delivery, it builds on Amazon's growing healthcare ecosystem.
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
In a candid interview, acclaimed author Emma Copley Eisenberg shares insights into her newest book Fat Swim, a collection of Philly-set stories exploring body image and identity. A self-identified fat liberationist, she critiques the rise of Ozempic ads and champions body autonomy amid shifting cultural attitudes toward fatness.
Ozempic and other GLP-1 medications are transforming figures in Hollywood and newsrooms alike, with before and after pics of personalities like Oprah Winfrey and Joy Behar showcasing undeniable weight loss. A 2024 study highlights their history since 1986, exploding in popularity post-Wegovy's 2021 FDA approval for weight loss. Spot the telltale Ozempic neck and hands that give away users.
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
The mantra 'once an accident, twice a coincidence, three times a trend' fuels bad journalism—and worse, risky medicine. A New Yorker investigation exposes clinics pushing unproven peptides for healing and longevity, backed by RFK Jr. While semaglutide proves the exception, most lack evidence and pose real harms.
